Top Mutual Funds
Pharmaceuticals company Alkem Laboratories announced Q1FY25 results:
- Total Revenue from Operations was Rs 30,318 million, with YoY growth of 2.2%.
- India sales were Rs 20,223 million, with YoY growth of 6.4%.
- International sales were Rs 9,677 million, with YoY de-growth of 4.6%.
- Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) were Rs 6,086 million, resulting in an EBITDA margin of 20.1% vs. 13.1% in Q1FY24. EBITDA increased by 56.4% YoY.
- R&D expenses for the quarter were Rs 1,257 million, or 4.1% of total revenue from operations, compared to Rs 1,202 million in Q1FY24 at 4.1% of total revenue from operations.
- Profit before tax (PBT) before exceptional items was Rs 6,194 million, a growth of 75.5% compared to Rs 3,529 million in Q1FY24.
- Net Profit (after Minority Interest) was Rs 5,452 million, with YoY growth of 90.1%.
- According to IQVIA (SSA—Stockist Sales Audit) data, for Q1FY25, the company registered a growth of 8.4% YoY compared to the Indian Pharmaceutical Market (IPM), which grew by 8.7%.
Commenting on the Q1FY25 results, Vikas Gupta, CEO of Alkem, said, “We are happy that our efforts to improve profitability have started paying off, and we have seen a marked increase in margins during the quarter. We are committed to maximising our EBITDA margin by carefully managing our product mix, controlling costs, and taking advantage of the favourable raw material pricing environment. The domestic business is our stronghold, and we expect to build on it by furthering the growth of our large brands and bridging portfolio gaps. Simultaneously, we are also focusing on growing our business in emerging markets. During the quarter, an important development was the successful resolution of US FDA’s Form 483 at the Baddi facility. At Alkem, we remain steadfast to prioritising quality and regulatory compliance.”
FAQ’s on Alkem Laboratories Ltd Shares
